MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that the medical journal Neuropsychopharmacology has published a new article on MN-166 written by Dr. Lara Ray and colleagues at the University of California, Los Angeles.  The article reports that MN-166 was associated with mood improvements on the stress- and alcohol-cue exposures, as well as reductions in overall craving, depression and anxiety for alcohol in subjects diagnosed with alcohol use disorder .  Moreover, in the subjects that had higher depressive symptomatology, MN-166 reduced the stimulant and mood-altering effects of alcohol compared to placebo.